AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
134 hedge funds and large institutions have $508M invested in AMAG Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 38 increasing their positions, 52 reducing their positions, and 28 closing their positions.
10% more capital invested
Capital invested by funds: $462M → $508M (+$46.1M)
5.55% more ownership
Funds ownership: 116.32% → 121.87% (+5.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
12% less call options, than puts
Call options by funds: $5.1M | Put options by funds: $5.81M
14% less funds holding
Funds holding: 156 → 134 (-22)
27% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 52
61% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$11.9M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$6.24M |
| 3 |
Morgan Stanley
New York
|
+$4.34M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.33M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.1M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.65M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1.95M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$1.81M |
AMAG Hedge Fund Activity: Q4 2019 in Review
134 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q4 2019, worth a combined $508M — up 10% from $462M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of AMAG and 11 opened new positions — a net loss of 17 holders — while 52 trimmed existing stakes and 38 added.
The largest buyer was Goldman Sachs, adding an estimated $11.9M. The largest seller was Millennium Management, cutting an estimated $3.4M.
- 134 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q4 2019, down from 156 in Q3 2019.
- Funds reported $508M of AMAG Pharmaceuticals stock for Q4 2019, up 10% quarter-over-quarter.
- 11 funds opened new AMAG Pharmaceuticals positions in Q4 2019 and 28 closed out, a net change of -17 holders.
- The largest AMAG Pharmaceuticals buyer in Q4 2019 was Goldman Sachs, an estimated $11.9M added.
- The largest AMAG Pharmaceuticals seller in Q4 2019 was Millennium Management, an estimated $3.4M sold.
Based on aggregated 13F filings for Q4 2019.